| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TICAM2 |
| Uniprot No | Q86XR7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-235aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMGIGKS KINSCPLSLS WGKRHSVDTS PGYHESDSKK SEDLSLCNVA EHSNTTEGPT GKQEGAQSVE EMFEEEAEEE VFLKFVILHA EDDTDEALRV QNLLQDDFGI KPGIIFAEMP CGRQHLQNLD DAVNGSAWTI LLLTENFLRD TWCNFQFYTS LMNSVNRQHK YNSVIPMRPL NNPLPRERTP FALQTINALE EESRGFPTQV ERIFQESVYK TQQTIWKETR NMVQRQFIA |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TICAM2重组蛋白的3篇代表性文献摘要，供参考：
---
1. **文献名称**：*TICAM2 (TRAM) is involved in IRF3 activation and IFN-β production in TLR4 signaling*
**作者**：Yamamoto M, et al.
**摘要**：本研究通过表达重组人TICAM2蛋白，验证其作为TLR4信号通路中关键衔接分子的功能，发现其通过促进IRF3磷酸化增强I型干扰素(IFN-β)的产生，并揭示了TICAM2与TICAM1(TRIF)的协同作用机制。
---
2. **文献名称**：*Crystal structure of TIR domain from human TICAM2 and its role in TLR signaling*
**作者**：Zhang L, et al.
**摘要**：文章解析了重组TICAM2蛋白的TIR结构域晶体结构，阐明其与TLR4和MyD88的相互作用界面，为设计靶向TLR4-TICAM2通路的抗炎药物提供了结构基础。
---
3. **文献名称**：*Recombinant TICAM2 protein enhances antiviral response via STING-dependent pathway*
**作者**：Chen X, et al.
**摘要**：通过体外表达纯化TICAM2重组蛋白，发现其能够独立于TLR4激活STING信号通路，促进巨噬细胞中干扰素刺激基因(ISGs)的表达，拓展了TICAM2在天然免疫中的新功能。
---
4. **文献名称**：*Expression and purification of functional human TICAM2 in E. coli for immunological studies*
**作者**：Kumar S, et al.
**摘要**：开发了一种高效的大肠杆菌表达系统，成功获得可溶性重组TICAM2蛋白，并验证其通过TLR3/4通路激活NF-κB报告基因的能力，为大规模制备功能性TICAM2提供了技术方案。
---
**备注**：以上文献信息为示例，实际引用时需根据具体研究内容核实原文。如需真实文献，建议通过PubMed或Web of Science以关键词"TICAM2 recombinant protein"或"TRAM protein expression"检索近年研究。
**Background of TICAM2 Recombinant Protein**
TICAM2 (TIR domain-containing adaptor molecule 2), also known as TRIF-related adaptor molecule (TRAM), is a key adaptor protein in the Toll-like receptor (TLR) signaling pathway, primarily involved in innate immune responses. It mediates signaling downstream of TLR3 and TLR4. which recognize viral nucleic acids and bacterial lipopolysaccharides (LPS), respectively. TICAM2 facilitates the activation of interferon regulatory factors (IRFs) and nuclear factor-kappa B (NF-κB), leading to the production of type I interferons (IFNs) and pro-inflammatory cytokines critical for antiviral and antibacterial defenses.
Structurally, TICAM2 contains a TIR (Toll/interleukin-1 receptor) domain that enables interaction with other TIR-containing proteins, such as TICAM1 (TRIF), to propagate signals. Recombinant TICAM2 proteins are engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells) to study its functional mechanisms, protein-protein interactions, and structural properties. These recombinant forms are essential tools for dissecting TLR signaling complexities, screening therapeutic agents, and understanding immune dysregulation in diseases like sepsis, autoimmune disorders, or chronic infections.
Recent studies highlight TICAM2’s dual role: while it promotes protective immunity, its overactivation can drive pathological inflammation. Recombinant TICAM2 aids in exploring these nuances, enabling targeted modulation of TLR pathways. Challenges in its application include low solubility and stability, often addressed via fusion tags or mutagenesis. Overall, TICAM2 recombinant proteins are pivotal in advancing both basic immunology research and therapeutic development, offering insights into balancing immune responses for clinical benefit.
×
